

Bruno Dubois

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11499075/publications.pdf>

Version: 2024-02-01

232
papers

53,453
citations

14124

69
h-index

2750

198
g-index

263
all docs

263
docs citations

263
times ranked

43670
citing authors

#	ARTICLE	IF	CITATIONS
1	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.	4.9	203
2	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
3	Toward noninvasive brain stimulation 2.0 in Alzheimer's disease. <i>Ageing Research Reviews</i> , 2022, 75, 101555.	5.0	37
4	Subtle postoperative cognitive disorder in preclinical Alzheimer's disease. <i>Experimental Gerontology</i> , 2022, 161, 111715.	1.2	0
5	Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 40.	3.0	30
6	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
7	Radiological classification of dementia from anatomical MRI assisted by machine learning-derived maps. <i>Journal of Neuroradiology</i> , 2021, 48, 412-418.	0.6	18
8	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	1.3	19
9	MiRNA-15b and miRNA-125b are associated with regional A β -PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints. <i>Translational Psychiatry</i> , 2021, 11, 78.	2.4	13
10	Plasma β -secretase1 concentrations correlate with basal forebrain atrophy and neurodegeneration in cognitively healthy individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2021, 17, 629-640.	0.4	10
11	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021, 17, 1528-1553.	0.4	64
12	Primary Progressive Aphasia Associated With <i>GRN</i> Mutations. <i>Neurology</i> , 2021, 97, e88-e102.	1.5	23
13	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	4.9	396
14	Awareness of Cognitive Decline in Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 697234.	1.7	17
15	A machine learning approach to screen for preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 105, 205-216.	1.5	18
16	Association of plasma A β ₄₀ /A β ₄₂ ratio and brain A β accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 107, 57-69.	1.5	5
17	Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12136.	1.8	12
18	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <i>European Journal of Neurology</i> , 2021, 28, 2147-2155.	1.7	20

#	ARTICLE	IF	CITATIONS
19	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Servicesâ€™ part 2 of 6. Alzheimer's Research and Therapy, 2021, 13, 169.	3.0	35
20	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Servicesâ€™ part 4 of 6. Alzheimer's Research and Therapy, 2021, 13, 171.	3.0	37
21	Impact of the New Conceptual Framework of Alzheimerâ€™s Disease in Imaging Studies. , 2021, , 427-451.		0
22	Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis. Frontiers in Aging Neuroscience, 2021, 13, 748198.	1.7	3
23	Recommendations of the International Working Group for the clinical diagnosis of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
24	Why donâ€™t Alzheimerâ€™s disease patients know that they forget?. Alzheimer's and Dementia, 2021, 17, .	0.4	0
25	Clinical diagnosis of Alzheimerâ€™s disease: Recommendations of the International Working Group (IWG). Alzheimer's and Dementia, 2021, 17, .	0.4	3
26	Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEGâ€fMRI study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
27	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiology of Aging, 2020, 85, 58-73.	1.5	150
28	Association of brain network dynamics with plasma biomarkers in subjective memory complainers. Neurobiology of Aging, 2020, 88, 83-90.	1.5	4
29	Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology, 2020, 94, e30-e41.	1.5	20
30	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
31	Î²-Secretase1 biological markers for Alzheimerâ€™s disease: state-of-art of validation and qualification. Alzheimer's Research and Therapy, 2020, 12, 130.	3.0	16
32	Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD. Alzheimer's Research and Therapy, 2020, 12, 129.	3.0	18
33	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	1.5	18
34	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59.	1.5	30
35	Age and sex impact plasma NFL and t-Tau trajectories in individuals with subjective memory complaints: a 3-year follow-up study. Alzheimer's Research and Therapy, 2020, 12, 147.	3.0	23
36	Does amnesia specifically predict Alzheimerâ€™s pathology? A neuropathological study. Neurobiology of Aging, 2020, 95, 123-130.	1.5	15

#	ARTICLE	IF	CITATIONS
37	Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain amyloid load. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12046.	1.8	7
38	Cognitive and behavioural inhibition deficits in neurodegenerative dementias. <i>Cortex</i> , 2020, 131, 265-283.	1.1	27
39	Reduced awareness of cognitive decline is associated with brain amyloid load in asymptomatic elderly individuals at risk for AD: A longitudinal study. <i>Alzheimer's and Dementia</i> , 2020, 16, e037138.	0.4	0
40	A specific pattern of memory errors in asymptomatic at-risk for AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e037385.	0.4	0
41	Solanezumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038028.	0.4	3
42	Gantenerumab in-depth outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e038049.	0.4	2
43	In-vivo characterization of progressive amnesic syndrome due to suspected neurodegenerative non-Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039587.	0.4	0
44	EEG: A valuable tool to screen for neurodegeneration in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e039696.	0.4	1
45	Alzheimer's disease brain atrophy subtypes are associated with incident dementia in subjective cognitive complaint and mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e039861.	0.4	2
46	Overview of dominantly inherited AD and top-line DIAN results of solanezumab and gantenerumab. <i>Alzheimer's and Dementia</i> , 2020, 16, e041129.	0.4	4
47	Association of plasma YKL40 with brain amyloidosis, memory performance, and sex in subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e041753.	0.4	0
48	Aging and sex impact plasma NFL and tau trajectories in individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041792.	0.4	2
49	Pathways involved in the relationship between resilience and cognitive function: The Memento cohort. <i>Alzheimer's and Dementia</i> , 2020, 16, e042674.	0.4	0
50	Predicting factors of cognitive progression in preclinical AD: A five-year follow-up of the insight study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042896.	0.4	0
51	Multimodal screening for neurodegeneration in preclinical Alzheimer's disease using EEG, APOE4 genotype, neuropsychological and MRI data. <i>Alzheimer's and Dementia</i> , 2020, 16, e044027.	0.4	0
52	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044711.	0.4	0
53	Cortical microstructural changes and amyloid beta burden in cognitively normal subjective memory complainers. <i>Alzheimer's and Dementia</i> , 2020, 16, e046014.	0.4	0
54	Sex differences in cortical microstructural changes in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046105.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1157-1166.	1.2	19
56	InÂvivo staging of regional amyloid deposition predicts functional conversion in the preclinical and prodromal phases of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 93, 98-108.	1.5	21
57	A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants. <i>Frontiers in Neurology</i> , 2020, 11, 571657.	1.1	11
58	lncRNAs as a novel source of diagnostic applications for early Alzheimerâ€™s disease and other dementia types. <i>Alzheimer's and Dementia</i> , 2020, 16, e039788.	0.4	0
59	Enlightening behavioral disturbances in myotonic dystrophy type 1 through neuropsychology and imaging correlations: Insights from the frontal and temporal lobe functions. <i>Alzheimer's and Dementia</i> , 2020, 16, e043114.	0.4	0
60	Which Episodic Memory Performance is Associated with Alzheimerâ€™s Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). <i>Journal of Alzheimer's Disease</i> , 2019, 70, 811-824.	1.2	16
61	Are PSP patients included in clinical trials representative of the general PSP population?. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 202-206.	1.1	3
62	How many patients are eligible for disease-modifying treatment in Alzheimerâ€™s disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	0.8	16
63	Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimerâ€™s disease: the INSIGHT-preAD Study. <i>Sleep</i> , 2019, 42, .	0.6	32
64	Language boosting by transcranial stimulation in progressive supranuclear palsy. <i>Neurology</i> , 2019, 93, e537-e547.	1.5	14
65	Brain AÎ² load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD. <i>Alzheimer's and Dementia</i> , 2019, 15, 1274-1285.	0.4	25
66	Latent class analysis identifies functional decline with Amsterdam IADL in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 553-562.	1.8	8
67	Does surface dyslexia/dysgraphia relate to semantic deficits in the semantic variant of primary progressive aphasia?. <i>Neuropsychologia</i> , 2019, 135, 107241.	0.7	3
68	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	1.5	48
69	Moral Emotions in Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 887-896.	1.2	10
70	Plasma amyloid Î² 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 764-775.	0.4	122
71	Differential default mode network trajectories in asymptomatic individuals at risk for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 940-950.	0.4	43
72	Alzheimer's Disease Including Focal Presentations. <i>Seminars in Neurology</i> , 2019, 39, 213-226.	0.5	72

#	ARTICLE	IF	CITATIONS
73	Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 15.	3.0	24
74	Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 18.	3.0	36
75	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
76	Relationship between Basal Forebrain Resting-State Functional Connectivity and Brain Amyloid- β Deposition in Cognitively Intact Older Adults with Subjective Memory Complaints. <i>Radiology</i> , 2019, 290, 167-176.	3.6	30
77	Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346.	4.9	161
78	Magnetic resonance imaging-based hippocampus volume for prediction of dementia in mild cognitive impairment: Why does the measurement method matter so little?. <i>Alzheimer's and Dementia</i> , 2018, 14, 976-978.	0.4	4
79	Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasia. <i>Neurology</i> , 2018, 90, e1057-e1065.	1.5	13
80	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
81	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β ₁₋₄₂ , total tau, phosphorylated tau, NFL, neurogranin, and YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, 492-501.	0.4	91
82	Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1855-1870.	3.7	111
83	The Emergence of a New Conceptual Framework for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1059-1066.	1.2	56
84	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
85	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. <i>NeuroImage: Clinical</i> , 2018, 17, 435-443.	1.4	19
86	P3-218: NOVEL ALZHEIMER'S DISEASE BIOMARKER-GUIDED DIAGNOSTIC WORKFLOW USING THE ADDED VALUE OF SIX COMBINED CEREBROSPINAL FLUID CANDIDATES: A β ₁₋₄₂ , TOTAL TAU, PHOSPHORYLATED TAU, NFL, NEUROGRANIN, AND YKL40. <i>Alzheimer's and Dementia</i> , 2018, 14, P1154.	0.4	1
87	P4-072: INCREASED PLASMA BACE1 CONCENTRATIONS IN WOMEN WITH SUBJECTIVE MEMORY COMPLAINTS: CORRELATION WITH PLASMA NFL. <i>Alzheimer's and Dementia</i> , 2018, 14, P1461.	0.4	0
88	P1-627: AMYLOID BURDEN IMPACTS EVERYDAY FUNCTIONING INDEPENDENT OF COGNITION AND AWARENESS IN SUBJECTIVE COGNITIVE DECLINE: FINDINGS FROM THE INSIGHT PRE-AD COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P581.	0.4	0
89	P3-411: CLINICAL SIGNIFICANCE OF IN-VIVO STAGING OF REGIONAL AMYLOID DEPOSITION IN SUBJECTIVE MEMORY COMPLAINERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1262.	0.4	0
90	P3-279: COGNITION AND LOW VISION: COGEVIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1185.	0.4	0

#	ARTICLE	IF	CITATIONS
91	P2â€237: ASSOCIATION OF CSF ALPHAâ€SYNUCLEIN AND TAU CONCENTRATIONS WITH AMYLOID MEAN CORTICAL STANDARD UPTAKE VALUE RATIOS IN PRECLINICAL SUBJECTIVE MEMORY COMPLAINERS STRATIFIED BY ALZHEIMER'S DISEASE BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2018, 14, P762.	0.4	0
92	O4â€07â€04: INCREASED RESILIENCE TO ALZHEIMER'S DISEASE PATHOPHYSIOLOGY IN MEN WITH SUBJECTIVE MEMORY COMPLAINTS COMPARED TO WOMEN. <i>Alzheimer's and Dementia</i> , 2018, 14, P1419.	0.4	0
93	O3â€09â€02: CORRELATION AND LONGITUDINAL DYNAMICS OF PLASMA NFL AND TAU CONCENTRATIONS IN AMYLOIDâ€PET NEGATIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1036.	0.4	0
94	P4â€186: INNOVATIVE BIOMARKERâ€GUIDED DIAGNOSTIC SYSTEM FROM PRECLINICAL TO ALZHEIMER'S DISEASE DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P1510.	0.4	0
95	P2â€246: INCREASED LONGITUDINAL DYNAMICS OF PLASMA YKLâ€40 CONCENTRATIONS IN AMYLOIDâ€PET POSITIVE INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P767.	0.4	0
96	P2â€249: CORRELATIONS AND ALTERED LONGITUDINAL DYNAMICS OF PLASMA BACE1 AND NFL CONCENTRATIONS IN INDIVIDUALS WITH SUBJECTIVE MEMORY COMPLAINTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P768.	0.4	0
97	P2â€277: CORTICAL SULCI WIDTH AND INCIDENT DEMENTIA IN OUTPATIENTS ATTENDING FRENCH MEMORY CLINICS: THE MEMENTO COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P784.	0.4	0
98	P4â€088: EVOLUTION OF THE AWARENESS OF COGNITIVE DECLINE INDEX OVER 24 MONTHS IN PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED TO BASELINE BRAIN AMYLOID LOAD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1469.	0.4	0
99	Parietal Involvement in the Semantic Variant of Primary Progressive Aphasia with Alzheimerâ€™s Disease Cerebrospinal Fluid Profile. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 271-280.	1.2	5
100	P1â€313: THE EATING BEHAVIOR INVENTORY (EBI): A 30â€ITEM CLINICAL TOOL TO DISTINGUISH FRONTOTEMPORAL DEMENTIA FROM BIPOLAR DISORDER. <i>Alzheimer's and Dementia</i> , 2018, 14, P411.	0.4	1
101	Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. <i>NeuroImage: Clinical</i> , 2018, 20, 1018-1025.	1.4	21
102	Neural correlates of episodic memory in the Memento cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 224-233.	1.8	23
103	Influence of Lewy Pathology on Alzheimerâ€™s Disease Phenotype: A Retrospective Clinico-Pathological Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1317-1323.	1.2	18
104	A mosquito bites and a butterfly flies: A specific response type of frontal patients in a similarity task. <i>Neuropsychologia</i> , 2018, 117, 371-378.	0.7	10
105	COGEVIS: A New Scale to Evaluate Cognition in Patients with Visual Deficiency. <i>Behavioural Neurology</i> , 2018, 2018, 1-7.	1.1	2
106	Association of cerebrospinal fluid β -synuclein with total and phospho τ ₁₈₁ protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018, 14, 1623-1631.	0.4	45
107	Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. <i>Alzheimer's and Dementia</i> , 2018, 14, 1204-1215.	0.4	79
108	Que penser de lâ€™approche mÃ©dicamenteuse prÃ©ventive de la maladie dâ€™Alzheimer ?. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2018, 202, 679-690.	0.0	0

#	ARTICLE	IF	CITATIONS
109	Free and Cued Selective Reminding Test " accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD). <i>Alzheimer's and Dementia</i> , 2017, 13, 913-923.	0.4	75
110	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.4	58
111	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.4	423
112	Two-level diagnostic classification using cerebrospinal fluid YKL40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.4	39
113	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 27.	3.0	66
114	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	1.9	46
115	Disrupted white matter structural networks in healthy older adult APOE ϵ 4 carriers " An international multicenter DTI study. <i>Neuroscience</i> , 2017, 357, 119-133.	1.1	31
116	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017, 55, 177-189.	1.5	20
117	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 153-166.	1.5	49
118	The biomarker-based diagnosis of Alzheimer's disease. "lessons from oncology. <i>Neurobiology of Aging</i> , 2017, 52, 141-152.	1.5	38
119	Determinants of theory of mind performance in Alzheimer's disease: A data-mining study. <i>Cortex</i> , 2017, 88, 8-18.	1.1	47
120	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	1.2	35
121	Effectiveness of Florbetapir PET Imaging in Changing Patient Management. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 129-143.	0.7	35
122	Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 11706.	1.6	79
123	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
124	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. <i>Neurobiology of Aging</i> , 2017, 59, 220.e1-220.e9.	1.5	116
125	[P1301]: THE MINI EATING BEHAVIOR INVENTORY (MINI EBI): A 10-ITEM CLINICAL TOOL FOR THE EARLY DIAGNOSIS OF FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2017, 13, P368.	0.4	0
126	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	4.9	464

#	ARTICLE	IF	CITATIONS
127	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.4	375
128	A common challenge in older adults: Classification, overlap, and therapy of depression and dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 59-71.	0.4	112
129	[P2â€“412]: A FUNCTIONAL RESTING STATE STUDY OF BASAL FOREBRAIN FUNCTIONAL CONNECTIVITY IN ASYMPTOMATIC ATâ€“RISK INDIVIDUALS FOR AD: THE INSIGHTâ€“READ STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P790.	0.4	0
130	[ICâ€“Pâ€“152]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€“STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€“PRE AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P114.	0.4	0
131	[P1â€“388]: DIFFERENT STRUCTURAL CONNECTIVITY PATTERNS IN MILD COGNITIVE IMPAIRMENT STRATIFIED BY AMYLOID AND NEURODEGENERATION BIOMARKERS. <i>Alzheimer's and Dementia</i> , 2017, 13, P414.	0.4	0
132	[P1â€“438]: SPONTANEOUS LOWâ€“FREQUENCY BOLD SIGNAL FLUCTUATIONS IN OLDER SUBJECTIVE MEMORY COMPLAINERS WITH OR WITHOUT BRAIN AMYLOIDOSIS: THE INSIGHTâ€“PREâ€“AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P450.	0.4	0
133	[P1â€“441]: ASSOCIATION OF CORTICAL AMYLOID LOAD WITH RESTINGâ€“STATE EEG FUNCTIONAL CONNECTIVITY IN SUBJECTIVE MEMORY COMPLAINERS FROM THE INSIGHTâ€“PREâ€“AD STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P451.	0.4	0
134	[P2â€“028]: EFFECT OF CHOLINESTERASE INHIBITORS ON BRAIN CHOLINERGIC STRUCTURES. <i>Alzheimer's and Dementia</i> , 2017, 13, P615.	0.4	0
135	[P4â€“236]: COMPARISON OF BRAIN MORPHOLOGY BETWEEN TWO DATABASES OF ELDERLY COGNITIVELY INTACT INDIVIDUALS FOR THE VALIDATION OF HIPPOCAMPAL VOLUME NORMATIVE DATA IN THE FRENCH INSIGHTâ€“PRE AD COHORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1364.	0.4	0
136	Alzheimerâ€™s Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 577-583.	1.2	2
137	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 67.	3.0	45
138	On the path to 2025: understanding the Alzheimerâ€™s disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	3.0	316
139	A phase III randomized trial of gantenerumab in prodromal Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 95.	3.0	396
140	Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1045-1054.	1.2	22
141	Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimerâ€™s Disease Regardless of Amnesia?. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1065-1074.	1.2	59
142	Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, 503-512.	0.3	27
143	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
144	So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1005-1014.	1.2	17

#	ARTICLE	IF	CITATIONS
145	Abolishing the 1â€year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	2.2	43
146	Direct current stimulation over the anterior temporal areas boosts semantic processing in primary progressive aphasia. <i>Annals of Neurology</i> , 2016, 80, 693-707.	2.8	47
147	Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimerâ€™s Disease Dementia in at Risk Subjects with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 867-873.	1.2	19
148	Drug development in Alzheimerâ€™s disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.	3.0	323
149	Functional Connectivity of Ventral and Dorsal Visual Streams in Posterior Cortical Atrophy. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1119-1130.	1.2	43
150	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
151	Early and protective microglial activation in Alzheimerâ€™s disease: a prospective study using ¹⁸ F-DPA-714 PET imaging. <i>Brain</i> , 2016, 139, 1252-1264.	3.7	365
152	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , The, 2016, 15, 455-532.	4.9	1,242
153	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	2.2	1,033
154	Prediction of Alzheimerâ€™s Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 793-804.	1.2	28
155	Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 199-209.	1.2	25
156	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S171-S191.	1.2	34
157	How Preserved is Emotion Recognition in Alzheimer Disease Compared With Behavioral Variant Frontotemporal Dementia?. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 154-157.	0.6	59
158	Timely Diagnosis for Alzheimerâ€™s Disease: A Literature Review on Benefits and Challenges. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 617-631.	1.2	330
159	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	2.2	4,389
160	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1041-1049.	0.4	102
161	Why do patients with neurodegenerative frontal syndrome fail to answer: â€œIn what way are an orange and a banana alike?â€™. <i>Brain</i> , 2015, 138, 456-471.	3.7	28
162	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.4	162

#	ARTICLE	IF	CITATIONS
163	Sulcal morphology as a new imaging marker for the diagnosis of early onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2932-2939.	1.5	39
164	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. <i>Alzheimer's and Dementia</i> , 2015, 11, 1306-1315.	0.4	104
165	Targeting Prodromal Alzheimer Disease With Avagacestat. <i>JAMA Neurology</i> , 2015, 72, 1324.	4.5	179
166	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
167	Taking stock: A multistakeholder perspective on improving the delivery of care and the development of treatments for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 455-461.	0.4	9
168	Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 58-69.	0.4	352
169	World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care. <i>International Journal of Psychiatry in Clinical Practice</i> , 2015, 19, 2-7.	1.2	23
170	Behavioral variant frontotemporal dementia patients do not succumb to the Allais paradox. <i>Frontiers in Neuroscience</i> , 2014, 8, 287.	1.4	7
171	Biological markers of Alzheimer's disease. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 227-231.	0.3	18
172	Frontal lobe neurology and the creative mind. <i>Frontiers in Psychology</i> , 2014, 5, 761.	1.1	47
173	Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing. <i>Movement Disorders</i> , 2014, 29, 1252-1257.	2.2	7
174	Recommendations for the use of Serious Games in people with Alzheimer's Disease, related disorders and frailty. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 54.	1.7	155
175	Two Distinct Amnesic Profiles in Behavioral Variant Frontotemporal Dementia. <i>Biological Psychiatry</i> , 2014, 75, 582-588.	0.7	86
176	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.4	1,863
177	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , 2014, 13, 614-629.	4.9	2,657
178	Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments. <i>Journal of Neurology</i> , 2014, 261, 1234-1243.	1.8	30
179	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, 808-817.	0.4	163
180	Detection of volume loss in hippocampal layers in Alzheimer's disease using 7T MRI: A feasibility study. <i>NeuroImage: Clinical</i> , 2014, 5, 341-348.	1.4	74

#	ARTICLE	IF	CITATIONS
181	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	2.2	379
182	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449.	2.0	105
183	Impact of the IWG/Dubois Criteria for Alzheimer's Disease in Imaging Studies. , 2014, , 309-322.		0
184	Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. <i>Brain</i> , 2013, 136, 3474-3488.	3.7	146
185	Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2013, 9, S84-94.	0.4	63
186	International Work Group Criteria for the Diagnosis of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 363-368.	1.1	72
187	A Critical Role for the Hippocampus in the Valuation of Imagined Outcomes. <i>PLoS Biology</i> , 2013, 11, e1001684.	2.6	89
188	The Diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease. <i>Focus (American Psychiatric Publishing)</i> , 2013, 11, 96-106.	0.4	241
189	Is Hippocampal Volume a Good Marker to Differentiate Alzheimer's Disease from Frontotemporal Dementia?. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 57-66.	1.2	79
190	The utility of the new research diagnostic criteria for Alzheimer's disease. <i>International Psychogeriatrics</i> , 2013, 25, 175-177.	0.6	14
191	The AD-CSF-Index Discriminates Alzheimer's Disease Patients from Healthy Controls: A Validation Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 67-77.	1.2	53
192	Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers. <i>Dementia E Neuropsychologia</i> , 2013, 7, 66-74.	0.3	29
193	Neuroimaging in dementias. <i>Current Opinion in Psychiatry</i> , 2012, 25, 473-479.	3.1	21
194	Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 695-698.	0.9	23
195	Temporal Order Memory Assessed during Spatiotemporal Navigation As a Behavioral Cognitive Marker for Differential Alzheimer's Disease Diagnosis. <i>Journal of Neuroscience</i> , 2012, 32, 1942-1952.	1.7	66
196	Effect of Six Months of Treatment with V0191 in Patients with Suspected Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 527-535.	1.2	9
197	Ask The Experts: New diagnostic criteria for Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 153-157.	1.2	0
198	Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. <i>Neurobiology of Aging</i> , 2012, 33, 1203-1214.e2.	1.5	346

#	ARTICLE	IF	CITATIONS
199	CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1253-1257.	1.5	91
200	Judgments about moral responsibility and determinism in patients with behavioural variant of frontotemporal dementia: Still compatibilists. <i>Consciousness and Cognition</i> , 2012, 21, 851-864.	0.8	20
201	Clinical and Research Diagnostic Criteria for Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 23-32.	0.5	51
202	Clinical validation of movement disorder society's recommended diagnostic criteria for Parkinson's disease with dementia. <i>Movement Disorders</i> , 2012, 27, 248-253.	2.2	51
203	Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 240-246.	0.9	168
204	Brain perfusion SPECT with an automated quantitative tool can identify prodromal Alzheimer's disease among patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2011, 32, 15-23.	1.5	80
205	AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. <i>Alzheimer's and Dementia</i> , 2011, 7, e109-17.	0.4	17
206	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging's Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 270-279.	0.4	7,498
207	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 474.	0.4	176
208	S2-02-01: Concepts of Preclinical Dementias. , 2011, 7, S280-S280.		0
209	New lexicon and criteria for the diagnosis of Alzheimer's disease " Authors' reply. <i>Lancet Neurology</i> , The, 2011, 10, 300-301.	4.9	7
210	Similar amyloid- β^2 burden in posterior cortical atrophy and Alzheimer's disease. <i>Brain</i> , 2011, 134, 2036-2043.	3.7	121
211	Biomarkers for the Early Stages of Clinical Development in Alzheimer's Disease. <i>Therapie</i> , 2010, 65, 285-290.	0.6	1
212	The Amnestic Syndrome of Hippocampal type in Alzheimer's Disease: An MRI Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 285-294.	1.2	141
213	Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 589-593.	3.3	22
214	Parkinson's disease dementia can be easily detected in routine clinical practice. <i>Movement Disorders</i> , 2010, 25, 2769-2776.	2.2	36
215	Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. <i>Neuroradiology</i> , 2009, 51, 73-83.	1.1	409
216	Clinical Investigations in Primary Care. <i>Frontiers of Neurology and Neuroscience</i> , 2009, 24, 1-11.	3.0	26

#	ARTICLE	IF	CITATIONS
217	Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. <i>NeuroImage</i> , 2009, 47, 1476-1486.	2.1	354
218	Relevance of the Evaluation Criteria Used in Clinical Trials for Alzheimer's Disease. <i>Therapie</i> , 2009, 64, 145-148.	0.6	5
219	Early detection of Alzheimer's disease: new diagnostic criteria. <i>Dialogues in Clinical Neuroscience</i> , 2009, 11, 135-139.	1.8	74
220	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	2.2	4,796
221	Revised research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2008, 7, 668-670.	4.9	21
222	Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. <i>Annals of Neurology</i> , 2008, 64, S81-S92.	2.8	122
223	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	2.2	1,097
224	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	2.2	2,497
225	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	2.2	885
226	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.	4.9	3,755
227	Apathy and the Functional Anatomy of the Prefrontal Cortex-Basal Ganglia Circuits. <i>Cerebral Cortex</i> , 2006, 16, 916-928.	1.6	1,025
228	Amnesic MCI or prodromal Alzheimer's disease?. <i>Lancet Neurology</i> , The, 2004, 3, 246-248.	4.9	459
229	Cognition, behavior and the frontal lobes. <i>International Psychogeriatrics</i> , 2004, 16, 379-387.	0.6	7
230	"Prodromal Alzheimer's disease": a more useful concept than mild cognitive impairment?. <i>Current Opinion in Neurology</i> , 2000, 13, 367-369.	1.8	59
231	Sensitivity to Semantic Cuing: An Index of Episodic Memory Dysfunction in Early Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, 38-46.	0.6	142
232	Subjective cognitive complaint. , 0, , 6-12.		0